Search Results

J-147 10 mg  | 99.61%

TargetMol

J-147 is an experimental drug with reported effects against both Alzheimer’s disease and ageing in mouse models of accelerated aging. It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy.

More Information Supplier Page

J-147 25 mg  | 99.61%

TargetMol

J-147 is an experimental drug with reported effects against both Alzheimer’s disease and ageing in mouse models of accelerated aging. It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy.

More Information Supplier Page

J-147 50 mg  | 99.61%

TargetMol

J-147 is an experimental drug with reported effects against both Alzheimer’s disease and ageing in mouse models of accelerated aging. It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy.

More Information Supplier Page

J-147 5 mg  | 99.61%

TargetMol

J-147 is an experimental drug with reported effects against both Alzheimer’s disease and ageing in mouse models of accelerated aging. It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy.

More Information Supplier Page

AT-56 5 mg  | 98.43%

TargetMol

AT56, a specific inhibitor of prostaglandin D2 synthase enzymatic activity, blunted adipogenic aldosterone effects.

More Information Supplier Page

AT-56 50 mg  | 98.43%

TargetMol

AT56, a specific inhibitor of prostaglandin D2 synthase enzymatic activity, blunted adipogenic aldosterone effects.

More Information Supplier Page